Developer docs
API playgroundTry for free, no card

Search company profiles

Cyrus Biotechnology

Full company profile

uuid0003b2r

Namestring
Cyrus Biotechnology
Legal namestring
Cyrus Biotechnology, Inc.
Websiteurl
cyrusbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cyrus Biotechnology is a Seattle-based pre-clinical-stage biologics discovery company that combines the Rosetta protein design platform with proprietary AI algorithms and large-scale deep mutagenesis laboratory screening to engineer natural proteins into improved therapeutics. Founded in 2015 by David Baker, Lucas Nivon, and Yifan Song as a spinout of the University of Washington Institute for Protein Design, the company has worked with more than 120 biopharma partners, including 13 of the top-20 global pharma firms, on 30+ active discovery programs. Its platform layers structure prediction (AlphaFold2, OpenFold), generative design (ProteinMPNN, Rosetta), and high-throughput experimental validation to optimize affinity, specificity, stability, solubility, half-life, and immunogenicity in parallel.

The company is building an internal pre-clinical pipeline led by CYR212, an IgG-cleaving IdeS variant for chronic IgG-driven autoimmune diseases such as generalized myasthenia gravis and immune thrombocytopenia that addresses an estimated greater than $20B clinical market opportunity. Other pipeline assets include an IL-22 fusion protein resistant to IL-22BP, a half-life-optimized IL-15 variant for oncology, an ACE2-IgG Fc decoy for ARDS, and an hCMV receptor decoy for congenital CMV. Beyond its internal pipeline, Cyrus offers Cyrus Bench, a SaaS protein engineering platform built on Rosetta, and co-founded the OpenFold consortium alongside Amazon, NVIDIA, Genentech/Prescient Design, Outpace Bio, and Arzeda to develop open-source protein AI foundation models; Cyrus CEO Lucas Nivon sits on OpenFold's four-person Executive Committee directing research priorities.

Cyrus operates a B2B partnerships business, monetizing through milestone- and royalty-bearing collaborations with biotech and pharma rather than direct software licensing. Representative partners include Janssen, Genentech, Nimbus Therapeutics, Selecta Biosciences, Broad Institute, Novo Nordisk, and Outpace Bio, with collaborations structured around upfront payments, discovery and development milestones, and sales-based royalties. In December 2024 the company spun out its protein AI and Rosetta services into Levitate Bio as a separate entity, signaling a narrowing of Cyrus's own commercial focus toward internal pipeline development.

Short descriptiontext

Cyrus Biotechnology is a Seattle-based pre-clinical biotech that uses Rosetta-based computational protein design, proprietary AI algorithms, and deep mutagenesis scanning to engineer improved biologics for pharma partners and advance an internal pipeline led by the IdeS candidate CYR212.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational protein design, biologics drug discovery, protein engineering platform, antibody structure prediction, biopharma research software
Industry5 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Computer Systems Design and Related Services54151
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Protein Design Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Collaborative Drug Discovery Partnerships
TypeLicensing Royalties
Description

Milestone and royalty-based collaborations with biotech and pharma companies. Cyrus provides protein engineering services and computational platform access in exchange for upfront payments, discovery/development milestones, and sales-based royalties. Examples include Selecta Biosciences collaboration for IL-2 protein agonists.

cyrusbio.com
2Acquisition of Orthogonal Biologics
TypeProfessional Services
Description

Acquired Orthogonal Biologics in December 2021 as part of $18M Series B financing to form integrated drug discovery firm with expanded capabilities in deep mutational scanning and internal pipeline development

cyrusbio.com
3Internal Drug Pipeline Development
TypeLicensing Royalties
Description

Advancing proprietary pre-clinical assets including CYR212 (IdeS for IgG-driven autoimmune disease), IL-22, IL-15, ACE2v2 for ARDS, and hCMV receptor decoy. Pipeline includes both internal programs and partnering pipeline programs.

cyrusbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Cyrus Bench
Description

SaaS platform for protein engineering

cyrusbio.com
+3 more records
Core offering1 text field

Cyrus Biotechnology operates an AI-enhanced computational protein design platform that combines the Rosetta software suite, proprietary AI algorithms, deep mutagenesis scanning, and large-scale laboratory screening. The company re-engineers natural proteins into superior therapeutics for biotech and pharma partners through integrated computational design and wet-lab iteration. It also advances an internal pre-clinical pipeline of engineered biologics candidates, including an engineered IgG protease (IdeS) for IgG-driven autoimmune disease and engineered immune cytokines (IL-22, IL-15), and co-founded the OpenFold open-source protein AI consortium.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • IdeS reduces IgG levels by >99% in minutes, compared to 60-80% reduction over days with FcRn blockers
+2 more records
Product overview1 text field

Cyrus Biotechnology is a computationally-driven biologics discovery company offering an integrated platform that combines AI-based protein design software (including Rosetta and proprietary algorithms), deep mutagenesis scanning capabilities, and wet laboratory protein engineering. The core platform enables re-engineering of natural proteins into superior therapeutics. Key products include internal pipeline candidates: CYR212 (IgG protease for autoimmune diseases), ACE2v2-Fc (ARDS therapeutic), Next-Gen IL-22 and IL-15 (immunocytokines), and hCMV Receptor Decoy. The company also offers Cyrus Bench, a SaaS protein engineering platform, and co-founded the OpenFold Consortium for open-source protein AI. Services include CRISPR optimization with Broad Institute and IL-2 agonist development with Selecta Biosciences.

Product and service8 records
1Cyrus Bio Platform
CategoryComputational protein design platform / services
Description

Computationally-driven biologics discovery platform combining AI, Rosetta computational methods, and large-scale laboratory screening for re-engineering natural proteins into superior therapeutics, delivered as collaborative discovery services for partner partners.

2Cyrus Bench
CategoryProtein engineering SaaS
Description

SaaS platform for protein engineering offering commercial access to Rosetta software and proprietary algorithms for structure prediction, mutagenesis, and protein design; used with top-20 pharma clients and cited in published protein stability research.

3OpenFold Consortium
CategoryOpen-source protein AI foundation models
Description

Non-profit AI research consortium co-founded by Cyrus with Amazon, NVIDIA, Genentech, Outpace, Arzeda, Mohammed AlQuraishi's lab and Bayer, developing open-source protein AI foundation models including OpenFold3 for proteins, nucleic acids, and drugs.

4CYR212 (Next-Gen IdeS)
CategoryInternal pre-clinical pipeline - IgG protease therapeutic
Description

Engineered IgG protease for chronic IgG-driven autoimmune diseases with improved half-life and 1000x reduced human antibody binding; selected as Cyrus's clinical candidate for myasthenia gravis and immune thrombocytopenia.

5ACE2v2-Fc
CategoryInternal pre-clinical pipeline - Fc fusion therapeutic
Description

Optimized ACE2-IgG Fc fusion protein with extended half-life and glycosylation optimization for treatment of Acute Respiratory Distress Syndrome; in early IND-enabling studies.

6Next-Gen IL-22
CategoryInternal pre-clinical pipeline - engineered cytokine
Description

IL-22 fusion protein engineered to be resistant to naturally occurring IL-22 Binding Protein with extended half-life; promotes tissue protection and regeneration for gastrointestinal, viral infection and metabolic indications.

7Next-Gen IL-15
CategoryInternal pre-clinical pipeline - engineered cytokine
Description

IL-15 variant with proprietary AI-designed slow-release modification that expands the therapeutic window by reducing toxicity; activates effector T-cells and NK cells for solid and hematologic tumor applications.

8hCMV Receptor Decoy
CategoryInternal pre-clinical pipeline - viral decoy therapeutic
Description

Engineered human cytomegalovirus receptor decoy with high specificity and extended half-life as a novel therapeutic for congenital CMV; in non-human primate studies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Orthogonal Biologics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired by Cyrus Biotechnology in December 2021 as part of $18M Series B financing. Deep mutational scanning protein engineering spin-out from University of Illinois at Urbana Champaign. Dr. Erik Procko, formerly CEO at Orthogonal Biologics, joined Cyrus as Director of Discovery. The acquisition provided unique mammalian cell-based deep mutational scanning capabilities.

cyrusbio.com
2Selecta Biosciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Protein engineering collaboration combining Selecta's ImmTOR platform with Cyrus' ability to radically redesign protein therapeutics. First program: proprietary IL-2 protein agonist designed to selectively promote expansion of regulatory T cells (Treg) for autoimmune diseases. Selecta provided upfront payment; Cyrus eligible for discovery, development and sales milestones.

cyrusbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-target collaboration to optimize CRISPR for human therapeutics by mitigating immune responses against CRISPR. Principal investigator: Feng Zhang (Howard Hughes Medical Institute). Researchers from Cyrus and Broad working together on deimmunization. Results to be published and freely available to academic community.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit AI research consortium co-founded by Cyrus in February 2022 with Mohammed AlQuraishi's lab, Genentech/Prescient Design, Outpace Bio, Arzeda, and others. Goal: develop free and open-source software tools for biology and drug discovery. Cyrus CEO Lucas Nivon serves on 4-person Executive Committee. OpenFold surpasses AlphaFold2 in speed and memory on NVIDIA chips.

Strategic tierMajorTypeTechnology or Integration
Description

Co-founder of OpenFold Consortium. Amazon provides cloud infrastructure and computational resources supporting the consortium's mission to develop open-source protein AI tools.

Strategic tierMajorTypeTechnology or Integration
Description

Co-founder of OpenFold Consortium. NVIDIA chips (Tesla T4, etc.) enable training and inference for protein AI models. OpenFold specifically tuned for commercial NVIDIA GPU chips.

Strategic tierMajorTypeTechnology or Integration
Description

Co-founder of OpenFold Consortium through Prescient Design. Contributing to development of open-source protein AI foundation models for drug discovery.

Strategic tierMajorTypeTechnology or Integration
Description

Co-founder of OpenFold Consortium. Early adopter of OpenFold3 for engineered cell-therapy circuits applications.

Strategic tierMajorTypeTechnology or Integration
Description

Co-founder of OpenFold Consortium. Contributing computational protein design expertise to open-source AI tools for biology.

Strategic tierStrategicTypeTechnology or Integration
Description

Joined OpenFold Consortium in November 2022. Interested in AI-driven pharmaceutical and agricultural product design. Dr. Ruth Wagner, VP Head of Plant Biotechnology Data Science at Bayer Crop Science leads engagement.

Strategic tierStrategicTypeTechnology or Integration
Description

Early adopter of OpenFold3 for small-molecule discovery applications as part of federated initiative through AI Structural Biology Network.

Strategic tierStrategicTypeTechnology or Integration
Description

Early adopter of OpenFold3 as part of AI Structural Biology Network with top-20 pharma companies leveraging proprietary structural data.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cyrus platform based on core Rosetta software from David Baker's lab at UW IPD. IPD achieved all major firsts in protein design including first designed protein and first de novo enzyme. Seattle region anchors world-class AI-driven biotech hub centered on IPD.

Strategic tierSupportingTypeGTM or Marketing Partner
Description

Nonprofit trade association helping Washington's $41.2B life sciences ecosystem communicate value to investors. Provides pitch coaching and narrative development. Working to connect biotech companies with Big Tech AI expertise.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public AI-driven drug discovery platform combining high-throughput biology with ML, serving similar biotech and pharma customer needs. Larger and broader in scope than Cyrus but directly comparable in computational drug-discovery partnerships with top-20 pharma.

TypeDirect peer
Description

Public computational chemistry and biologics platform combining physics-based modeling with ML for drug discovery. Directly overlaps Cyrus on AI/ML-enabled protein structure prediction and biologics design, and was the named competitor in Cyrus's BIOCAD benchmark.

TypeDirect peer
Description

AI-driven generative biology company creating novel protein therapeutics using machine learning. Competes with Cyrus for AI-engineered biologic partnerships with top-20 pharma and operates in the same protein-design platform category.

TypeEmerging player
Description

AI protein engineering platform focused on programmable biology for therapeutics and industrial applications. Comparable in stage and AI-protein approach but with broader small-molecule and enzyme focus than Cyrus's biologics orientation.

5Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed drug discovery company building on DeepMind's AlphaFold, combining AI protein structure prediction with pharma partnerships. A deep-pocketed competitor targeting the same top-pharma biologics-discovery wallet share.

TypeDirect peer
Description

Public antibody discovery platform combining AI/high-throughput screening with pharma partnerships. Overlaps with Cyrus's NextGen Antibody offering and competes for the same antibody-engineering economics from top-20 pharma partners.

TypeEmerging player
Description

AI/ML-driven antibody design company combining ML with wet-lab validation for next-generation antibodies. Direct overlap on antibody engineering use cases and competes for the same AI-biologics partnerships with pharma.

TypeDirect peer
Description

Computational protein design company co-founding OpenFold with Cyrus. Works on protein design for therapeutics and industrial applications, with overlapping AI/structure-prediction capabilities and shared consortium infrastructure.

TypeEmerging player
Description

AI protein language model company developing foundation models for biology. Adjacent competitor for AI-protein infrastructure, contributing to the same open-vs-closed debate that Cyrus navigates via OpenFold consortium leadership.

TypeDirect peer
Description

Cell-therapy company using AI-driven protein design to engineer smart cells. Co-founder in the OpenFold consortium and direct collaborator/competitor in applying Cyrus-style protein engineering to immuno-oncology and cell therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyrus Biotechnology

Computational Protein Design Platformcyrusbio.com

Cyrus Biotechnology is a Seattle-based pre-clinical biotech that uses Rosetta-based computational protein design, proprietary AI algorithms, and deep mutagenesis scanning to engineer improved biologics for pharma partners and advance an internal pipeline led by the IdeS candidate CYR212.

What Cyrus Biotechnology does

Cyrus Biotechnology is a Seattle-based pre-clinical-stage biologics discovery company that combines the Rosetta protein design platform with proprietary AI algorithms and large-scale deep mutagenesis laboratory screening to engineer natural proteins into improved therapeutics. Founded in 2015 by David Baker, Lucas Nivon, and Yifan Song as a spinout of the University of Washington Institute for Protein Design, the company has worked with more than 120 biopharma partners, including 13 of the top-20 global pharma firms, on 30+ active discovery programs. Its platform layers structure prediction (AlphaFold2, OpenFold), generative design (ProteinMPNN, Rosetta), and high-throughput experimental validation to optimize affinity, specificity, stability, solubility, half-life, and immunogenicity in parallel.

The company is building an internal pre-clinical pipeline led by CYR212, an IgG-cleaving IdeS variant for chronic IgG-driven autoimmune diseases such as generalized myasthenia gravis and immune thrombocytopenia that addresses an estimated greater than $20B clinical market opportunity. Other pipeline assets include an IL-22 fusion protein resistant to IL-22BP, a half-life-optimized IL-15 variant for oncology, an ACE2-IgG Fc decoy for ARDS, and an hCMV receptor decoy for congenital CMV. Beyond its internal pipeline, Cyrus offers Cyrus Bench, a SaaS protein engineering platform built on Rosetta, and co-founded the OpenFold consortium alongside Amazon, NVIDIA, Genentech/Prescient Design, Outpace Bio, and Arzeda to develop open-source protein AI foundation models; Cyrus CEO Lucas Nivon sits on OpenFold's four-person Executive Committee directing research priorities.

Cyrus operates a B2B partnerships business, monetizing through milestone- and royalty-bearing collaborations with biotech and pharma rather than direct software licensing. Representative partners include Janssen, Genentech, Nimbus Therapeutics, Selecta Biosciences, Broad Institute, Novo Nordisk, and Outpace Bio, with collaborations structured around upfront payments, discovery and development milestones, and sales-based royalties. In December 2024 the company spun out its protein AI and Rosetta services into Levitate Bio as a separate entity, signaling a narrowing of Cyrus's own commercial focus toward internal pipeline development.

Cyrus Biotechnology firmographics

Firmographics
Name
Cyrus Biotechnology
Legal name
Cyrus Biotechnology, Inc.
Website
https://cyrusbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cyrus Biotechnology is a Seattle-based pre-clinical biotech that uses Rosetta-based computational protein design, proprietary AI algorithms, and deep mutagenesis scanning to engineer improved biologics for pharma partners and advance an internal pipeline led by the IdeS candidate CYR212.
Ownership category
akta.pro rank

Cyrus Biotechnology industry classification

Industry
Product category
Computational Protein Design Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Computer Systems Design and Related Services (54151)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational protein design
  • Biologics drug discovery
  • Protein engineering platform
  • Antibody structure prediction
  • Biopharma research software

Where Cyrus Biotechnology is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cyrus Biotechnology business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Collaborative Drug Discovery Partnerships: Milestone and royalty-based collaborations with biotech and pharma companies. Cyrus provides protein engineering services and computational platform access in exchange for upfront payments, discovery/development milestones, and sales-based royalties. Examples include Selecta Biosciences collaboration for IL-2 protein agonists.
  2. Acquisition of Orthogonal Biologics: Acquired Orthogonal Biologics in December 2021 as part of $18M Series B financing to form integrated drug discovery firm with expanded capabilities in deep mutational scanning and internal pipeline development
  3. Internal Drug Pipeline Development: Advancing proprietary pre-clinical assets including CYR212 (IdeS for IgG-driven autoimmune disease), IL-22, IL-15, ACE2v2 for ARDS, and hCMV receptor decoy. Pipeline includes both internal programs and partnering pipeline programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cyrus Biotechnology product offering

Product offering

Core offering

Cyrus Biotechnology operates an AI-enhanced computational protein design platform that combines the Rosetta software suite, proprietary AI algorithms, deep mutagenesis scanning, and large-scale laboratory screening. The company re-engineers natural proteins into superior therapeutics for biotech and pharma partners through integrated computational design and wet-lab iteration. It also advances an internal pre-clinical pipeline of engineered biologics candidates, including an engineered IgG protease (IdeS) for IgG-driven autoimmune disease and engineered immune cytokines (IL-22, IL-15), and co-founded the OpenFold open-source protein AI consortium.

Product overview

Cyrus Biotechnology is a computationally-driven biologics discovery company offering an integrated platform that combines AI-based protein design software (including Rosetta and proprietary algorithms), deep mutagenesis scanning capabilities, and wet laboratory protein engineering. The core platform enables re-engineering of natural proteins into superior therapeutics. Key products include internal pipeline candidates: CYR212 (IgG protease for autoimmune diseases), ACE2v2-Fc (ARDS therapeutic), Next-Gen IL-22 and IL-15 (immunocytokines), and hCMV Receptor Decoy. The company also offers Cyrus Bench, a SaaS protein engineering platform, and co-founded the OpenFold Consortium for open-source protein AI. Services include CRISPR optimization with Broad Institute and IL-2 agonist development with Selecta Biosciences.

Differentiator

Problem solved

Functional benefit

Brands

  • Cyrus Bench: SaaS platform for protein engineering
  • Cyrus IdeS
  • CYR212
  • ACE2v2

Products and services

  • Cyrus Bio Platform Computationally-driven biologics discovery platform combining AI, Rosetta computational methods, and large-scale laboratory screening for re-engineering natural proteins into superior therapeutics, delivered as collaborative discovery services for partner partners.
  • Cyrus Bench SaaS platform for protein engineering offering commercial access to Rosetta software and proprietary algorithms for structure prediction, mutagenesis, and protein design; used with top-20 pharma clients and cited in published protein stability research.
  • OpenFold Consortium Non-profit AI research consortium co-founded by Cyrus with Amazon, NVIDIA, Genentech, Outpace, Arzeda, Mohammed AlQuraishi's lab and Bayer, developing open-source protein AI foundation models including OpenFold3 for proteins, nucleic acids, and drugs.
  • CYR212 (Next-Gen IdeS) Engineered IgG protease for chronic IgG-driven autoimmune diseases with improved half-life and 1000x reduced human antibody binding; selected as Cyrus's clinical candidate for myasthenia gravis and immune thrombocytopenia.
  • ACE2v2-Fc Optimized ACE2-IgG Fc fusion protein with extended half-life and glycosylation optimization for treatment of Acute Respiratory Distress Syndrome; in early IND-enabling studies.
  • Next-Gen IL-22 IL-22 fusion protein engineered to be resistant to naturally occurring IL-22 Binding Protein with extended half-life; promotes tissue protection and regeneration for gastrointestinal, viral infection and metabolic indications.
  • Next-Gen IL-15 IL-15 variant with proprietary AI-designed slow-release modification that expands the therapeutic window by reducing toxicity; activates effector T-cells and NK cells for solid and hematologic tumor applications.
  • hCMV Receptor Decoy Engineered human cytomegalovirus receptor decoy with high specificity and extended half-life as a novel therapeutic for congenital CMV; in non-human primate studies.

Quantifiable outcome

  • IdeS reduces IgG levels by >99% in minutes, compared to 60-80% reduction over days with FcRn blockers
  • +2 more outcomes

Companies that use Cyrus Biotechnology

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Cyrus Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Cyrus Biotechnology partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, major, strategic and supporting.

  • Orthogonal BiologicscoreStrategic or Co-development PartnerAcquired by Cyrus Biotechnology in December 2021 as part of $18M Series B financing. Deep mutational scanning protein engineering spin-out from University of Illinois at Urbana Champaign. Dr. Erik Procko, formerly CEO at Orthogonal Biologics, joined Cyrus as Director of Discovery. The acquisition provided unique mammalian cell-based deep mutational scanning capabilities.
  • Selecta BiosciencescoreStrategic or Co-development PartnerProtein engineering collaboration combining Selecta's ImmTOR platform with Cyrus' ability to radically redesign protein therapeutics. First program: proprietary IL-2 protein agonist designed to selectively promote expansion of regulatory T cells (Treg) for autoimmune diseases. Selecta provided upfront payment; Cyrus eligible for discovery, development and sales milestones.
  • Broad Institute of MIT and HarvardcoreStrategic or Co-development PartnerMulti-target collaboration to optimize CRISPR for human therapeutics by mitigating immune responses against CRISPR. Principal investigator: Feng Zhang (Howard Hughes Medical Institute). Researchers from Cyrus and Broad working together on deimmunization. Results to be published and freely available to academic community.
  • OpenFold ConsortiumcoreStrategic or Co-development PartnerNon-profit AI research consortium co-founded by Cyrus in February 2022 with Mohammed AlQuraishi's lab, Genentech/Prescient Design, Outpace Bio, Arzeda, and others. Goal: develop free and open-source software tools for biology and drug discovery. Cyrus CEO Lucas Nivon serves on 4-person Executive Committee. OpenFold surpasses AlphaFold2 in speed and memory on NVIDIA chips.
  • AmazonmajorTechnology or IntegrationCo-founder of OpenFold Consortium. Amazon provides cloud infrastructure and computational resources supporting the consortium's mission to develop open-source protein AI tools.
  • NVIDIAmajorTechnology or IntegrationCo-founder of OpenFold Consortium. NVIDIA chips (Tesla T4, etc.) enable training and inference for protein AI models. OpenFold specifically tuned for commercial NVIDIA GPU chips.
  • GenentechmajorTechnology or IntegrationCo-founder of OpenFold Consortium through Prescient Design. Contributing to development of open-source protein AI foundation models for drug discovery.
  • Outpace BiomajorTechnology or IntegrationCo-founder of OpenFold Consortium. Early adopter of OpenFold3 for engineered cell-therapy circuits applications.
  • ArzedamajorTechnology or IntegrationCo-founder of OpenFold Consortium. Contributing computational protein design expertise to open-source AI tools for biology.
  • BayerstrategicTechnology or IntegrationJoined OpenFold Consortium in November 2022. Interested in AI-driven pharmaceutical and agricultural product design. Dr. Ruth Wagner, VP Head of Plant Biotechnology Data Science at Bayer Crop Science leads engagement.
  • Novo NordiskstrategicTechnology or IntegrationEarly adopter of OpenFold3 for small-molecule discovery applications as part of federated initiative through AI Structural Biology Network.
  • Bayer Crop SciencestrategicTechnology or IntegrationEarly adopter of OpenFold3 as part of AI Structural Biology Network with top-20 pharma companies leveraging proprietary structural data.
  • University of Washington Institute for Protein Design (IPD)coreStrategic or Co-development PartnerCyrus platform based on core Rosetta software from David Baker's lab at UW IPD. IPD achieved all major firsts in protein design including first designed protein and first de novo enzyme. Seattle region anchors world-class AI-driven biotech hub centered on IPD.
  • Life Science WashingtonsupportingGTM or Marketing PartnerNonprofit trade association helping Washington's $41.2B life sciences ecosystem communicate value to investors. Provides pitch coaching and narrative development. Working to connect biotech companies with Big Tech AI expertise.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Cyrus Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput biology with ML, serving similar biotech and pharma customer needs. Larger and broader in scope than Cyrus but directly comparable in computational drug-discovery partnerships with top-20 pharma.
  • Isomorphic Labs: Alphabet-backed drug discovery company building on DeepMind's AlphaFold, combining AI protein structure prediction with pharma partnerships. A deep-pocketed competitor targeting the same top-pharma biologics-discovery wallet share.

Direct peers

  • Schrödinger: Public computational chemistry and biologics platform combining physics-based modeling with ML for drug discovery. Directly overlaps Cyrus on AI/ML-enabled protein structure prediction and biologics design, and was the named competitor in Cyrus's BIOCAD benchmark.
  • Generate Biomedicines: AI-driven generative biology company creating novel protein therapeutics using machine learning. Competes with Cyrus for AI-engineered biologic partnerships with top-20 pharma and operates in the same protein-design platform category.
  • AbCellera: Public antibody discovery platform combining AI/high-throughput screening with pharma partnerships. Overlaps with Cyrus's NextGen Antibody offering and competes for the same antibody-engineering economics from top-20 pharma partners.
  • Arzeda: Computational protein design company co-founding OpenFold with Cyrus. Works on protein design for therapeutics and industrial applications, with overlapping AI/structure-prediction capabilities and shared consortium infrastructure.
  • Outpace Bio: Cell-therapy company using AI-driven protein design to engineer smart cells. Co-founder in the OpenFold consortium and direct collaborator/competitor in applying Cyrus-style protein engineering to immuno-oncology and cell therapy.

Emerging players

  • Cradle Bio: AI protein engineering platform focused on programmable biology for therapeutics and industrial applications. Comparable in stage and AI-protein approach but with broader small-molecule and enzyme focus than Cyrus's biologics orientation.
  • BigHat Biosciences: AI/ML-driven antibody design company combining ML with wet-lab validation for next-generation antibodies. Direct overlap on antibody engineering use cases and competes for the same AI-biologics partnerships with pharma.
  • EvolutionaryScale (ESM): AI protein language model company developing foundation models for biology. Adjacent competitor for AI-protein infrastructure, contributing to the same open-vs-closed debate that Cyrus navigates via OpenFold consortium leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cyrus Biotechnology social profiles

Digital presence

Cyrus Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyrus Biotechnology leadership team

Management profile

Number of profiles

Profiles11 records

Cyrus Biotechnology subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Cyrus Biotechnology funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyrus Biotechnology M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyrus Biotechnology

What does Cyrus Biotechnology do?

Cyrus Biotechnology operates an AI-enhanced computational protein design platform that combines the Rosetta software suite, proprietary AI algorithms, deep mutagenesis scanning, and large-scale laboratory screening. The company re-engineers natural proteins into superior therapeutics for biotech and pharma partners through integrated computational design and wet-lab iteration. It also advances an internal pre-clinical pipeline of engineered biologics candidates, including an engineered IgG protease (IdeS) for IgG-driven autoimmune disease and engineered immune cytokines (IL-22, IL-15), and co-founded the OpenFold open-source protein AI consortium.

Is Cyrus Biotechnology a public or private company?

Cyrus Biotechnology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cyrus Biotechnology founded?

Cyrus Biotechnology was founded in 2015. It employs 11 to 50 people.

Where is Cyrus Biotechnology based?

Cyrus Biotechnology is headquartered in Seattle, United States, in the North America region.

How does Cyrus Biotechnology make money?

Three revenue lines are on record. Collaborative Drug Discovery Partnerships are the primary driver. The others are acquisition of Orthogonal Biologics and internal Drug Pipeline Development.

Who are Cyrus Biotechnology's main competitors?

Broad incumbents on record are Recursion Pharmaceuticals and Isomorphic Labs. Direct peers are Schrödinger, Generate Biomedicines, AbCellera, Arzeda and Outpace Bio. Emerging players are Cradle Bio, BigHat Biosciences and EvolutionaryScale (ESM).

Does Cyrus Biotechnology have an API?

No public API is recorded for Cyrus Biotechnology.

What industry is Cyrus Biotechnology in?

Cyrus Biotechnology's product category is Computational Protein Design Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune ThrombocytopeniaCyrus Biotechnology announced the selection of CYR212, an engineered IgG protease, as its clinical development candidate for treating chronic IgG-driven autoimmune diseases such as Myasthenia Gravis and Immune Thrombocytopenia. The company cites promising preclinical data showing extended half-life and reduced immunogenicity compared to existing therapies, positioning it to address a potential $20 billion market. Cyrus plans to advance CYR212 into clinical studies targeting indications where current best-in-class anti-FcRn therapeutics have limitations in potency or dosing convenience.BroadinstituteScientists engineer CRISPR enzymes that evade the immune systemResearchers at the Broad Institute of MIT and Harvard, in partnership with Cyrus Biotechnology, have engineered two CRISPR nucleases (Cas9 and Cas12) to evade the human immune system by identifying and redesigning protein sequences that trigger immune responses. The engineered enzymes demonstrated significantly reduced immune responses while maintaining the same gene-editing efficiency as standard nucleases in both human cells and genetically modified mice. The findings, published in Nature Communications, could advance the development of safer, more effective gene therapies for clinical use.YahooCyrus Biotechnology to spin out Levitate Bio for biopharma AICyrus Biotechnology announced the spin-out of Levitate Bio to provide automated, custom AI solutions for drug discovery. The new entity will operate as a wholly-owned subsidiary of the Rosetta Commons Foundation, leveraging the Rosetta biomolecular modelling suite. Levitate Bio aims to serve a broader market including synthetic biology and manufacturing.YahooCyrus Biotechnology to spin out Levitate Bio for biopharma AICyrus Biotechnology announced the spin-out of Levitate Bio to provide automated, custom AI solutions for drug discovery. The new entity will be a wholly-owned subsidiary of the Rosetta Commons Foundation, leveraging the Rosetta biomolecular modelling suite. Levitate Bio aims to serve a broader market including synthetic biology and manufacturing.American City Business JournalsCyrus Biotechnology acquires Orthogonal BiologicsSeattle-based Cyrus Biotechnology has acquired Orthogonal Biologics, a University of Illinois spinout specializing in protein drugs for viruses like SARS-CoV-2. This acquisition follows an $18 million Series B funding round and marks Cyrus's transition from a software services provider to an independent drug discovery entity. Financial terms of the deal were not disclosed.Business Wire BlogCyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery FirmCyrus Biotechnology closed an $18M Series B financing and acquired Orthogonal Biologics, combining its software platform with deep mutational scanning protein engineering. The combined firm will focus on biologics discovery for infectious disease, rheumatology, rare diseases, and auto-immune disorders, with a pipeline including a COVID-19 therapeutic.SecSEC FORM DCyrus Biotechnology, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of equity securities under Rule 506(b). The filing indicates that the company raised a total of $15,942,168 USD from 35 investors, with the first sale occurring on June 22, 2021. The offering was signed by CEO Lucas Nivon in October 2021.GeekWireSeattle startup Cyrus inks protein-design deal with immune biotech Selecta worth up to $1.5 billionSeattle-based Cyrus Biotechnology and Boston-based Selecta Biosciences announced a protein engineering collaboration worth up to $1.5 billion, focused on developing new agents for immune-related conditions. The partnership's lead program involves combining an immune-modulating agent from Selecta with IL-2 proteins engineered by Cyrus using its proprietary software tools. This deal adds to Cyrus's existing portfolio of multi-year collaborations, including work with the Broad Institute.PR NewswireInsights on the Synthetic DNA Global Market to 2027 - Featuring Codexis, Creative Enzymes and Cyrus Biotechnology Among OthersResearch and Markets has added a new market report titled "Synthetic DNA - Global Market Trajectory & Analytics" to its offerings, projecting the global synthetic DNA market to grow from US$1.3 billion in 2020 to US$4.2 billion by 2027 at an 18% CAGR. The report highlights significant regional growth, with China forecast to reach nearly US$1 billion by 2027, while detailing performance projections for segments such as Pharmaceuticals & Diagnostics and Biofuels. Key industry players featured in the analysis include Codexis, Creative Enzymes, Cyrus Biotechnology, and Twist Bioscience.GeekWireCyrus Biotechnology and CRISPR pioneers team up to boost gene-editing therapiesSeattle-based Cyrus Biotechnology has entered a collaboration with the Broad Institute of MIT and Harvard to optimize CRISPR gene-editing techniques for human therapeutics. The partnership, led by MIT biochemist Feng Zhang at the Broad Institute, aims to reduce potential immune responses against CRISPR therapies while making results freely available to the scientific community.